Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

582 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prise en charge du trouble de consommation d’opioïdes en première ligne: Lignes directrices simplifiées de PEER.
Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ. Korownyk C, et al. Among authors: reich k. Can Fam Physician. 2019 May;65(5):e173-e184. Can Fam Physician. 2019. PMID: 31088882 Free PMC article. French.
Managing opioid use disorder in primary care: PEER simplified guideline.
Korownyk C, Perry D, Ton J, Kolber MR, Garrison S, Thomas B, Allan GM, Bateman C, de Queiroz R, Kennedy D, Lamba W, Marlinga J, Mogus T, Nickonchuk T, Orrantia E, Reich K, Wong N, Dugré N, Lindblad AJ. Korownyk C, et al. Among authors: reich k. Can Fam Physician. 2019 May;65(5):321-330. Can Fam Physician. 2019. PMID: 31088869 Free PMC article.
Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA).
Reich K, Bianchi L, Khemis A, Maul JT, Tsianakas A, Schempp CM, Petersen K, Noergaard MM, Puig L. Reich K, et al. Dermatol Ther (Heidelb). 2024 Feb;14(2):453-468. doi: 10.1007/s13555-023-01092-x. Epub 2024 Feb 1. Dermatol Ther (Heidelb). 2024. PMID: 38300408 Free PMC article.
Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study.
Papp K, Warren RB, Green L, Reich K, Langley RG, Paul C, Asahina A, Johnson L, Arora V, Osuntokun O, Lebwohl M. Papp K, et al. Among authors: reich k. Lancet Rheumatol. 2023 Sep;5(9):e542-e552. doi: 10.1016/S2665-9913(23)00120-0. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251498 Clinical Trial.
Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study.
Guttman-Yassky E, Simpson EL, Reich K, Kabashima K, Igawa K, Suzuki T, Mano H, Matsui T, Esfandiari E, Furue M. Guttman-Yassky E, et al. Among authors: reich k. Adv Ther. 2024 Mar;41(3):928-931. doi: 10.1007/s12325-023-02755-z. Epub 2024 Jan 8. Adv Ther. 2024. PMID: 38185777 Free PMC article. Clinical Trial.
Correction to: Assessment of Efficacy and Safety Outcomes Beyond Week 16 in Clinical Trials of Systemic Agents Used for the Treatment of Moderate to Severe Atopic Dermatitis in Combination with Topical Corticosteroids.
Silverberg JI, Armstrong A, Blauvelt A, Reich K. Silverberg JI, et al. Among authors: reich k. Am J Clin Dermatol. 2024 Jan;25(1):163. doi: 10.1007/s40257-023-00828-x. Am J Clin Dermatol. 2024. PMID: 38008857 Free PMC article. No abstract available.
582 results